908 Devices Launches Real-Time Monitoring Platform For Multiple Bioprocess Parameters
October 4, 2023
Source: drugdu
110
The device, Maverick, utilizes Raman spectroscopy for bioprocess control.
908 Devices Inc. launched Maverick, an optical in-line analyzer that provides real-time monitoring for multiple bioprocess controls. The device also provides control of glucose, lactate, and total biomass in mammalian cell cultures.
According to a press release from 908 Devices, this is the first turn-key device that utilizes Raman spectroscopy for bioprocess control without also requiring modeling or development.
Christopher D. Brown, chief product officer and co-founder of 908 Devices, said in a press release, “As the biopharmaceutical industry adopts Process Analytical Technologies to drive the advancement of Biopharma 4.0, scientists need an array of tools that enable them to monitor and control their process in real time."
He continued, "We are addressing this need with our full complement of devices. With MAVERICK, we are introducing a new platform that offers easy-to-integrate in-line analysis and control without the need for substantial expert configuration or set-up. In addition, as a spectroscopic-based device, MAVERICK is extensible to other analytes and parameters.”
Copyright©2024 Ddu. All rights reserved.
Read more on
- Is the turning point of “Cosmic Pharmaceutical Factory” coming? November 2, 2024
- It is better to look at the long-term situation November 2, 2024
- Domestic TCE polyclonal antibodies are “surging” November 2, 2024
- Medici Globalization Strategy Accelerates, Overseas Business Reaches New Heights November 2, 2024
- Ensuring patients’ peace of mind through the stable operation of medical insurance institutions and enterprises – the medical insurance department is intensifying efforts to introduce incremental policies to serve and safeguard the overall development November 2, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
